李晓曦

个人信息：Personal Information

讲师硕士生导师

教师拼音名称：lixiaoxi

电子邮箱：lixiaoxi@ujs.edu.cn

所在单位：医学院

办公地点：医学院2号楼1221室

职称：讲师

毕业院校：分子细胞科学卓越创新中心

硕士生导师

学科：临床检验诊断学

扫描关注

同专业硕导

Hemann Lab

当前位置： M&T研究小组 >> 前沿进展 >> Hemann Lab

Michael T. Hemann

Associate Professor of Biology; Intramural Faculty, Koch Institute

Ludwig Center at MIT’s Koch Institute for Integrative Cancer Research

Koch Institute for Integrative Cancer Research At MIT

Michael T. Hemann - MIT Department of Biology

Professor Hemann uses high throughput genetics and tractable pre-clinical models to investigate basic mechanisms of cancer drug resistance.

LAB WEBSITE： Home | Hemann Lab (mit.edu)

Mike Hemann’s training and research has focused development of models of cancer evolution and therapeutic response. Michael T. Hemann, PhD | Hemann Lab (mit.edu)

As a post-doctoral fellow in Scott Lowe’s laboratory at Cold Spring Harbor Laboratory, he sought to develop tractable mouse models that could be used with the same ease as classic genetic model organisms to interrogate the genetics of cancer progression and treatment.

As a graduate student, he investigated mouse models of telomere dysfunction in Carol Greider’s laboratory.

The result of these efforts has been the development of diverse approaches that be directly applied to investigating mechanisms of tumor drug resistance.

Their consistent objective is the development of combination drug regimens that can subvert the evolution of drug resistance.

They have also been able to extend this work into the clinic in the context of treatment refractory malignancies.

The Hemann lab has pioneered the development of novel screening strategies to characterize the genetic determinants of drug action in relevant physiological settings.

A particular focus of this work is to develop strategies to sensitize tumors to front-line chemotherapy.

His group has made extensive use of mice as preclinical systems to examine therapeutic efficacy and have developed hematopoietic and solid tumor models that can effectively interrogate aspects of acquired and intrinsic drug resistance.

Research Summary：Many human cancers do not respond to chemotherapy, and often times those that initially respond eventually acquire drug resistance. Our lab uses high-throughput screening technology — combined with murine stem reconstitution and tumor transplantation systems — to investigate the genetic basis for this resistance. Our goal is to identify novel cancer drug targets, as well as strategies for tailoring existing cancer therapies to target the vulnerabilities associated with specific malignancies.

Research Interests：Using mouse models to combat cancers resistant to chemotherapy.

1. Microenvironmental Drug Resistance

2. In vivo screening for modulators of drug response

3. Examining single and combination mechanisms of drug action

独立实验室科研工作(hemann mt[Author - Last]) AND Massachusetts Institute of Technology[Affiliation] - Search Results - PubMed (nih.gov)

Research Highlight

In Vivo RNAi Screen for BMI1 Targets Identifies TGF-β/BMP-ER Stress Pathways as Key Regulators of Neural- and Malignant Glioma-Stem Cell Homeostasis: Cancer Cell

Unraveling Tumor Suppressor Networks with In Vivo RNAi: Cell Stem Cell

A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC | Cancer Discovery | American Association for Cancer Research (aacrjournals.org)

From Breaking Bad to Worse: Exploiting Homologous DNA Repair Deficiency in Cancer | Cancer Discovery | American Association for Cancer Research (aacrjournals.org)

综述

Chemotherapeutic Resistance: Surviving Stressful Situations | Cancer Research | American Association for Cancer Research (aacrjournals.org)